{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:38:37Z","timestamp":1790231917034,"version":"4.1.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bisphosphonates bind avidly to bone mineral and are potent inhibitors of osteoclast-mediated bone destruction. They also exhibit antitumor activity in vitro. Here, we used a mouse model of human breast cancer bone metastasis to examine the effects of risedronate and NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, on osteolysis and tumor growth. Osteolysis was measured by radiography and histomorphometry. Tumor burden was measured by fluorescence imaging and histomorphometry. NE-10790 had a 70-fold lower bone mineral affinity compared with risedronate. It was 7-fold and 8,800-fold less potent than risedronate at reducing, respectively, breast cancer cell viability in vitro and bone loss in ovariectomized animals. We next showed that risedronate given at a low dosage in animals bearing human B02-GFP breast tumors reduced osteolysis by inhibiting bone resorption, whereas therapy with higher doses also inhibited skeletal tumor burden. Conversely, therapy with NE-10790 substantially reduced skeletal tumor growth at a dosage that did not inhibit osteolysis, a higher dosage being able to also reduce bone destruction. The in vivo antitumor activity of NE-10790 was restricted to bone because it did not inhibit the growth of subcutaneous B02-GFP tumor xenografts nor the formation of B16-F10 melanoma lung metastases. Moreover, NE-10790, in combination with risedronate, reduced both osteolysis and skeletal tumor burden, whereas NE-10790 or risedronate alone only decreased either tumor burden or osteolysis, respectively. In conclusion, our study shows that decreasing the bone mineral affinity of bisphosphonates is an effective therapeutic strategy to inhibit skeletal tumor growth in vivo. [Cancer Res 2008;68(21):8945\u201353]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2195","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T03:57:40Z","timestamp":1225339060000},"page":"8945-8953","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition\n                    <i>In vivo<\/i>"],"prefix":"10.1158","volume":"68","author":[{"given":"Pierrick G.J.","family":"Fournier","sequence":"first","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Research Unit UMR 664, Faculte\u0301 de Me\u0301decine Laennec, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Daubine\u0301","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Research Unit UMR 664, Faculte\u0301 de Me\u0301decine Laennec, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Lundy","sequence":"additional","affiliation":[{"name":"4Procter and Gamble Pharmaceuticals, Mason, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rogers","sequence":"additional","affiliation":[{"name":"3Institute of Medical Sciences, Aberdeen, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[{"name":"4Procter and Gamble Pharmaceuticals, Mason, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cle\u0301zardin","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Research Unit UMR 664, Faculte\u0301 de Me\u0301decine Laennec, Lyon, France;"},{"name":"2Universite\u0301 Claude Bernard Lyon 1, Villeurbanne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"2022061700281524700_B1","doi-asserted-by":"crossref","unstructured":"Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis\u20082007; 24: 599\u2013608.","DOI":"10.1007\/s10585-007-9112-8"},{"key":"2022061700281524700_B2","doi-asserted-by":"crossref","unstructured":"Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer\u20082008; 98: 1736\u201340.","DOI":"10.1038\/sj.bjc.6604382"},{"key":"2022061700281524700_B3","doi-asserted-by":"crossref","unstructured":"Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol\u20082006; 6: 307\u201312.","DOI":"10.1016\/j.coph.2006.03.005"},{"key":"2022061700281524700_B4","doi-asserted-by":"crossref","unstructured":"Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure-activity relationsgips among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem\u20082008; 51: 2187\u201395.","DOI":"10.1021\/jm7015733"},{"key":"2022061700281524700_B5","doi-asserted-by":"crossref","unstructured":"Stresing V, Daubine F, Benzaid I, Mo\u0308nkko\u0308nen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett\u20082007; 257: 16\u201335.","DOI":"10.1016\/j.canlet.2007.07.007"},{"key":"2022061700281524700_B6","unstructured":"Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res\u20081997; 57: 3890\u201394."},{"key":"2022061700281524700_B7","doi-asserted-by":"crossref","unstructured":"Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone\u20082008; 42: 848\u201360.","DOI":"10.1016\/j.bone.2007.12.225"},{"key":"2022061700281524700_B8","doi-asserted-by":"crossref","unstructured":"Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus, Sulfur, Silicon\u20081996; 109: 217\u201320.","DOI":"10.1080\/10426509608046237"},{"key":"2022061700281524700_B9","doi-asserted-by":"crossref","unstructured":"van Beek ER, Lo\u0308wik CWGM, Ebetino FH, Papapoulos SE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationship. Bone\u20081998; 23: 437\u201342.","DOI":"10.1016\/S8756-3282(98)00120-3"},{"key":"2022061700281524700_B10","unstructured":"Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res\u20082000; 60: 2949\u201354."},{"key":"2022061700281524700_B11","doi-asserted-by":"crossref","unstructured":"Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RGG, Shipman CM. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer\u20082006; 119: 1254\u201361.","DOI":"10.1002\/ijc.21977"},{"key":"2022061700281524700_B12","doi-asserted-by":"crossref","unstructured":"Coxon FP, Helfrich MH, Larijani B, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem\u20082001; 276: 48213\u201322.","DOI":"10.1074\/jbc.M106473200"},{"key":"2022061700281524700_B13","doi-asserted-by":"crossref","unstructured":"Pe\u0301cheur I, Peyruchaud O, Serre CM, et al. Integrin \u03b1(v)\u03b23 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J\u20082002; 16: 1266\u20138 (10.1096\/fj.01\u20130911fje).","DOI":"10.1096\/fj.01-0911fje"},{"key":"2022061700281524700_B14","doi-asserted-by":"crossref","unstructured":"Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone\u20082006; 38: 617\u201327.","DOI":"10.1016\/j.bone.2005.05.003"},{"key":"2022061700281524700_B15","unstructured":"Ebetino FH, Emmerling P, Barnett B, Nancollas GH. Differentiation of hydroxyapatite affinity of bisphosphonate analogs for mechanism of action studies [abstract SA305]. J Bone Miner Res\u20082004; 19: s157."},{"key":"2022061700281524700_B16","doi-asserted-by":"crossref","unstructured":"Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A\u20082006; 103: 9643\u20138.","DOI":"10.1073\/pnas.0600979103"},{"key":"2022061700281524700_B17","doi-asserted-by":"crossref","unstructured":"Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res\u20082001; 16: 2027\u201334.","DOI":"10.1359\/jbmr.2001.16.11.2027"},{"key":"2022061700281524700_B18","doi-asserted-by":"crossref","unstructured":"Teitelbaum SL. Bone resorption by osteoclasts. Science\u20082000; 289: 1504\u20138.","DOI":"10.1126\/science.289.5484.1504"},{"key":"2022061700281524700_B19","doi-asserted-by":"crossref","unstructured":"Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst\u20082007; 99: 322\u201330.","DOI":"10.1093\/jnci\/djk054"},{"key":"2022061700281524700_B20","doi-asserted-by":"crossref","unstructured":"Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone\u20082005; 37: 349\u201358.","DOI":"10.1016\/j.bone.2005.04.021"},{"key":"2022061700281524700_B21","doi-asserted-by":"crossref","unstructured":"Lackner MR, Kindt RM, Carroll PM, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target for farnesyl transferase inhibitors. Cancer Cell\u20082005; 7: 325\u201336.","DOI":"10.1016\/j.ccr.2005.03.024"},{"key":"2022061700281524700_B22","doi-asserted-by":"crossref","unstructured":"Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of Rab GTPases in cancer and human disease. Cancer Res\u20082005; 65: 2516\u20139.","DOI":"10.1158\/0008-5472.CAN-05-0573"},{"key":"2022061700281524700_B23","doi-asserted-by":"crossref","unstructured":"Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-\u03baB ligand pathway. Cancer Res\u20082005; 65: 11001\u20139.","DOI":"10.1158\/0008-5472.CAN-05-2630"},{"key":"2022061700281524700_B24","doi-asserted-by":"crossref","unstructured":"Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res\u20082006; 134: 44\u201351.","DOI":"10.1016\/j.jss.2006.03.018"},{"key":"2022061700281524700_B25","doi-asserted-by":"crossref","unstructured":"Degraeve F, Bolla M, Blaie S, et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. J Biol Chem\u20082001; 276: 46849\u201355.","DOI":"10.1074\/jbc.M104197200"},{"key":"2022061700281524700_B26","doi-asserted-by":"crossref","unstructured":"Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res\u20082008; 14: 4658\u201366.","DOI":"10.1158\/1078-0432.CCR-07-1545"},{"key":"2022061700281524700_B27","doi-asserted-by":"crossref","unstructured":"Lipton A. Emerging role of bisphosphonates in the clinic. Antitumor activity and prevention of metastasis to bone. Cancer Treat Rev\u20082008; 34: S25\u201330.","DOI":"10.1016\/j.ctrv.2008.03.008"},{"key":"2022061700281524700_B28","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract LBA4]. J Clin Oncol 2008;26.","DOI":"10.1200\/jco.2008.26.15_suppl.lba4"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/21\/8945\/2599454\/8945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/21\/8945\/2599454\/8945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T01:01:42Z","timestamp":1709341302000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/21\/8945\/542046\/Lowering-Bone-Mineral-Affinity-of-Bisphosphonates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,30]]},"references-count":28,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2008,10,30]]},"published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2195","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6498036.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375953.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498036","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375950.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375950","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375947.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375947","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375944.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375941.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375941","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375953","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375944","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,30]]}}}